Grant: Master's Award: Canada Graduate Scholarships
Toronto Metropolitan University
$17,500.00
Essential role of clathrin signalosomes in receptor signaling in cancer cells.
EF 2018-19
Résumé
Cells communicate with each other through chemical cues, each of which can trigger a specific cell response. For instance, epidermal growth factor (EGF) elicits a cellular response when it binds to epidermal growth factor receptor (EGFR). EGFR is a receptor on the cell surface that controls much of what cells can do such as growth, movement (migration) and survival. Therefore, EGFR must be tightly regulated by the cell. When this control fails, this can lead to growth, survival and metastasis of many tumors. Our lab has identified a new function for the protein clathrin inside cells to control the function of EGFR and thus its ability to control cell growth and survival. Clathrin forms tiny structures that are a few nanometers long, that critically also contain other proteins called TOM1L1 and Fyn. These tiny clathrin structure are critical to control EGFR; however, we do not fully understand how these dynamic protein assemblies form, and how specifically they are able to control the oncogene EGFR.
To better understand how clathrin controls EGFR, I will use fluorescently-tagged versions of the key proteins clathrin, TOM1L1 and Fyn alongside labelled EGFR in living cancer cells, coupled to advanced microscopy. Using this and computer-based automated image analysis, I will learn how clathrin protein assemblies control the key oncogene EGFR in certain cancers. The significance of this research is that understanding this novel role of clathrin has the potential to reveal new weakness of certain cancers that can be thus targeted with new drugs.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
406630
Name
Cabral-Dias Rebecca
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Essential role of clathrin signalosomes in receptor signaling in cancer cells.
Programtype2
Studentship Programs
Orgnameinp2
Toronto Metropolitan University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer; Clathrin; Drug Research; Endocytosis; Epidermal Growth Factor Receptor; Innovative; Oncogenic; Src Family Kinase; Total Internal Reflection Fluorescence Microscopy; Tyrosine Kinase Receptor
Abstract
Cells communicate with each other through chemical cues, each of which can trigger a specific cell response. For instance, epidermal growth factor (EGF) elicits a cellular response when it binds to epidermal growth factor receptor (EGFR). EGFR is a receptor on the cell surface that controls much of what cells can do such as growth, movement (migration) and survival. Therefore, EGFR must be tightly regulated by the cell. When this control fails, this can lead to growth, survival and metastasis of many tumors. Our lab has identified a new function for the protein clathrin inside cells to control the function of EGFR and thus its ability to control cell growth and survival. Clathrin forms tiny structures that are a few nanometers long, that critically also contain other proteins called TOM1L1 and Fyn. These tiny clathrin structure are critical to control EGFR; however, we do not fully understand how these dynamic protein assemblies form, and how specifically they are able to control the oncogene EGFR.
To better understand how clathrin controls EGFR, I will use fluorescently-tagged versions of the key proteins clathrin, TOM1L1 and Fyn alongside labelled EGFR in living cancer cells, coupled to advanced microscopy. Using this and computer-based automated image analysis, I will learn how clathrin protein assemblies control the key oncogene EGFR in certain cancers. The significance of this research is that understanding this novel role of clathrin has the potential to reveal new weakness of certain cancers that can be thus targeted with new drugs.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Cabral-Dias, Rebecca
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~